ASCO 2014: Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma

Abstract No: 8594 Background: Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US…

read more

Tommy Garceau, IMBCR’s Marathon Team Captain

Tommy, who has been Dr. Berenson’s able assistant for many years, has a passion for…

read more

Talking About Myeloma with Loved Ones

Do you feel the Love? The New Year is here. Perhaps you have been newly…

read more

Counterpoints: Do Patients With Multiple Myeloma Need Maintenance Treatment?

By Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3 Multiple myeloma…

read more

KIIS Cares Interview

What: Myeloma is a disease in your bone marrow. Inside your bone marrow are the…

read more

IMBCR Identifies New Treatments for Myeloma in 2015!

First, we have made much progress on our new protein marker called B-cell maturation antigen…

read more

I Have WHAT? An Interview With Patient Advocate Debra Berenson

Interview with Debra Berenson, myeloma patient advocate, wife of myeloma expert Dr. James Berenson, and…

read more

To Transplant or Not To Transplant in Multiple Myeloma

Clinical Advances in Hematology & Oncology [button style=”download” link=”https://www.hematologyandoncology.net/files/2014/05/ho0514_counter1.pdf” color=”teal”]Download Paper[/button] Authors: James R. Berenson,…

read more

Advances in the Management of Multiple Myeloma

James R Berenson, MD,abc Tanya M Spektor, PhD,c and James Wang, MDab aInstitute for Myeloma…

read more

Replacement of Bortezomib with Carfilzomib for Multiple Myeloma Patients Progressing from Bortezomib Combination Therapy

J R Berenson1,2,3, J D Hilger2, O Yellin2, R Dichmann4, D Patel-Donnelly5, R V Boccia6, A Bessudo7, L Stampleman8, D Gravenor9, S Eshaghian10, Y Nassir11, R…

read more
Previous Posts
Next Posts